Esperion Therapeutics (ESPR) Operating Income: 2018-2025
Historic Operating Income for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$10.0 million.
- Esperion Therapeutics' Operating Income rose 37.86% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.4 million, marking a year-over-year decrease of 278.55%. This contributed to the annual value of $54.4 million for FY2024, which is 134.97% up from last year.
- Latest data reveals that Esperion Therapeutics reported Operating Income of -$10.0 million as of Q3 2025, which was down 240.37% from $7.1 million recorded in Q2 2025.
- Esperion Therapeutics' 5-year Operating Income high stood at $72.3 million for Q1 2024, and its period low was -$82.8 million during Q1 2021.
- Moreover, its 3-year median value for Operating Income was -$16.0 million (2024), whereas its average is -$11.5 million.
- Its Operating Income has fluctuated over the past 5 years, first surged by 248.69% in 2024, then tumbled by 130.57% in 2025.
- Esperion Therapeutics' Operating Income (Quarterly) stood at -$55.6 million in 2021, then increased by 23.58% to -$42.5 million in 2022, then climbed by 0.34% to -$42.4 million in 2023, then soared by 89.57% to -$4.4 million in 2024, then spiked by 37.86% to -$10.0 million in 2025.
- Its Operating Income stands at -$10.0 million for Q3 2025, versus $7.1 million for Q2 2025 and -$22.1 million for Q1 2025.